Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

ClinicalTrials.gov ID: NCT03507790

Public ClinicalTrials.gov record NCT03507790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Study identification

NCT ID
NCT03507790
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cognition Therapeutics
Industry
Enrollment
153 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2018
Primary completion
May 28, 2024
Completion
May 28, 2024
Last update posted
Aug 10, 2025

2018 – 2024

United States locations

U.S. sites
12
U.S. states
5
U.S. cities
12
Facility City State ZIP Site status
21st Century Neurology/ Xenoscience Inc. Phoenix Arizona 85004
Imaging Endpoints Scottsdale Arizona 85258
Ki Health Partners, LLC dba New England Institute for Clinical Research Stamford Connecticut 06905
JEM Research Institute Atlantis Florida 33462
Charter Research Lady Lake Florida 32159
ClinCloud, LLC Maitland Florida 32751
Allied Biomedical Research Institute Miami Florida 33155
Compass Research LLC- Bioclinica Research The Villages Florida 32162
ClinCloud Viera Florida 32940
Alzheimer's Memory Center Charlotte North Carolina 28270
The Ohio State University - Wexner Columbus Ohio 43221-3502
Neuro Behavirol Clinical Research C North Canton Ohio 44720

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03507790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03507790 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →